Roy Wiesner

Roy Wiesner has held various roles in the healthcare and biotechnology industries since 2013. From 2013-2015, they served as CEO of Hutchison Kinrot. In 2015, they became Chairman of the Board of Clairion Ltd., a venture formation of MercuRemoval (now Clairion) that holds patented gas treatment technology. From 2016-2018, they were a Board Member and lead investor (seed round) of TripleW Ltd., a company that develops an industrial bioprocess for the conversion of organic waste into highly pure lactic acid and bioplastics. In 2018, they became a Board Member and lead investor (Series A) of AtaCor Medical, Inc., a company developing the world's first pacing system that keeps the heart and veins free from pacing leads and hardware. Roy also became a Board Member and lead investor (Series A) of Igentify, a bioinformatics company providing advanced preventive healthcare through genomic products and services. Additionally, they became an Observer - Investment Committee of RMGP Biopharma Investment Fund and Managing Director of aMoon Fund, a leading HealthTech & Life Sciences venture fund. In 2019, they became a Board Member and Lead investor (Series A) of Ibex Medical Analytics, an Artificial Intelligence (AI) software company developing computational pathology solutions. In 2021, they became a Board Member and Lead Investor (Seed Round) of Eleos Health, a company powering the future of behavioral health.

Roy Wiesner's education history includes a Bachelor of Law (LL.B.) from The Hebrew University of Jerusalem, which they obtained between 1998 and 2002. Roy then went on to pursue a Master of Public Administration (MPA) from The London School of Economics and Political Science (LSE) from 2003 to 2004. In 2004, they completed a second MPA from Columbia | SIPA. In 2011, they completed an Executive Education program from Harvard Business School in Leadership.